- Home
- SSM vs KPRX Comparison
SSM vs KPRX Comparison
Compare SSM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSM
- KPRX
- Stock Information
- Founded
- SSM N/A
- KPRX 1998
- Country
- SSM Germany
- KPRX United States
- Employees
- SSM 43
- KPRX N/A
- Industry
- SSM
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SSM
- KPRX Health Care
- Exchange
- SSM Nasdaq
- KPRX Nasdaq
- Market Cap
- SSM 9.9M
- KPRX 9.2M
- IPO Year
- SSM N/A
- KPRX N/A
- Fundamental
- Price
- SSM $6.64
- KPRX $1.87
- Analyst Decision
- SSM
- KPRX Strong Buy
- Analyst Count
- SSM 0
- KPRX 1
- Target Price
- SSM N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SSM N/A
- KPRX 51.4K
- Earning Date
- SSM N/A
- KPRX 11-07-2025
- Dividend Yield
- SSM N/A
- KPRX N/A
- EPS Growth
- SSM N/A
- KPRX N/A
- EPS
- SSM N/A
- KPRX N/A
- Revenue
- SSM N/A
- KPRX N/A
- Revenue This Year
- SSM N/A
- KPRX N/A
- Revenue Next Year
- SSM N/A
- KPRX N/A
- P/E Ratio
- SSM N/A
- KPRX N/A
- Revenue Growth
- SSM N/A
- KPRX N/A
- 52 Week Low
- SSM N/A
- KPRX $1.79
- 52 Week High
- SSM N/A
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SSM N/A
- KPRX 27.45
- Support Level
- SSM N/A
- KPRX $1.79
- Resistance Level
- SSM N/A
- KPRX $2.39
- Average True Range (ATR)
- SSM 0.00
- KPRX 0.11
- MACD
- SSM 0.00
- KPRX -0.04
- Stochastic Oscillator
- SSM 0.00
- KPRX 8.24
About SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.